Compare VEON & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VEON | AAPG |
|---|---|---|
| Founded | 1992 | 2009 |
| Country | United Arab Emirates | China |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 2.9B |
| IPO Year | 1996 | 2025 |
| Metric | VEON | AAPG |
|---|---|---|
| Price | $50.14 | $32.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $73.25 | $48.50 |
| AVG Volume (30 Days) | ★ 118.8K | 5.1K |
| Earning Date | 11-10-2025 | 11-19-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 8.91 | N/A |
| Revenue | ★ $4,226,000,000.00 | $54,524,554.00 |
| Revenue This Year | $10.26 | N/A |
| Revenue Next Year | $7.61 | $368.64 |
| P/E Ratio | $5.65 | ★ N/A |
| Revenue Growth | ★ 6.74 | N/A |
| 52 Week Low | $34.05 | $16.50 |
| 52 Week High | $64.00 | $48.45 |
| Indicator | VEON | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 48.74 | 50.39 |
| Support Level | $48.68 | $30.00 |
| Resistance Level | $54.66 | $33.09 |
| Average True Range (ATR) | 1.98 | 0.83 |
| MACD | -0.05 | 0.14 |
| Stochastic Oscillator | 36.64 | 72.07 |
VEON Ltd is a United Arab Emirates-based digital operator providing connectivity and Internet services to corporations and individuals. The company offers mobile and fixed-line telecommunications services through a range of traditional and broadband mobile technologies. The company's reportable segments consist of the following five segments: Pakistan, Ukraine, Kazakhstan, Bangladesh, and Uzbekistan. It provides its services under the Beeline, Kyivstar, Banglalink, and Jazz brands. It generates the majority of its revenue from Pakistan.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.